Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets

Gennisium finds a strategic partner with global experience and connections in the pharmaceutical industry to accelerate its development in neonatology.

Pierre Fabre strengthens its activities in the field of rare diseases,and more specifically pediatric ones.

This partnership paves the way for further collaboration between the two companies and marks a milestone for their respective growth strategy in neonatology/pediatrics,rare diseases and niche/orphan drugs.

CASTRES,France and VITROLLES,France,Oct. 10,2022 -- The Pierre Fabre Group and Gennisium Pharma have announced an agreement whereby Pierre Fabre takes a minority stake in Gennisium through its dedicated investment subsidiary Pierre Fabre Invest.

Gennisium's company mission is to provide newborn patients with suitable medicines,based on affordable prices and with global reach. To this end,Gennisium is looking to reposition known molecules for neonatal indications and to provide health care professionals and neonatal intensive care units with novel and suitable formulations along with the medicines they need to prevent or treat neonatal diseases and conditions.

Franck Pigache,CEO,Gennisium Pharma,commented: "We are very pleased with this investment and to now have such a strong partner as Pierre Fabreamong our shareholders - a major player and a successful company with solid experience in the pharmaceutical industry and the specific field of pediatrics. With their backing,Gennisium will have additional means and latitude to pursue its growth. New drugs are under development and Pierre Fabre's investment will allow us to accelerate the registration and availability of those products."

Alongside oncology and dermatology,Pierre Fabre is increasingly involved in the field of rare diseases,with a special focus on diseases affecting newborns,developing specific and prophylactic therapies for this patient population in need for adapted treatments. Such is the approach adopted for infantile hemangioma since 2014 and,more recently,for XLHED,a rare genetic disease affecting the sweat and respiratory glands,skin,hair and teeth conditions of baby boys.

Eric Ducournau,Pierre Fabre Group,said: "We are delighted to be working with Gennisium Pharma,a young,innovative pharmaceutical company developing formulations for premature babies and niche markets. Through this investment,we confirm our willingness to explore new opportunities in the field of rare pediatric diseases where patient and family needs remain immense."

Both companies are already working together to provide this fragile population of patients with therapeutic advances. By joining forces with Pierre Fabre,Gennisium finds a strong partner with global experience and connections in the pharmaceutical industry to accelerate its development in neonatology. Pierre Fabre will help Gennisium build up its product portfolio,its organization and its market access across the world,by investing in existing operations,potential licensing agreements and expertise sharing in the field of neonatology and pediatrics.

For more information about Pierre Fabre,please visit the website www.pierre-fabre.com

For more information about Gennisium,please visit the website https://gennisium.com

Pierre Fabre

Anne KERVEILLANT

anne.kerveillant@pierre-fabre.com

Lys Avocat

Siham Belarbi

s.belarbi@lysavocats.com

Gennisium Pharma

Frank PIGACHE,CEO

fpigache@gennisium.com